Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Congratulations from CCTG! The Canadian Cancer Society (CCS) has funded its first research grant focused specifically on rare and aggressive uterine cancers, a critical first step to better outcomes for people with these cancers to Dr Stephanie Lheureux.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth).
The PR22 (ANZUP 1801) study DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer has been centrally activated in Canada.
CCTG would like to extend congratulations to Dr. Kelvin Chan the recipient of the 2020 Dr. Maurice McGregor Award from Canadian Agency for Drugs and Technologies in Health (CADTH). The Dr. Maurice McGregor Award, honours rising stars early in their careers.
Congratulations to our CCTG Hematologic Disease Site Chair, Dr. Tony Reiman, who has been successfully reappointed as the Canadian Cancer Society Research Chair at the University of New Brunswick.
Great news to share from the CCTG IC8 trial team! The study already has 6 sites currently participating with 29 patients accrued. Congrats to all of the trial teams at:
